I am perplexed. The product makes sense yet no pathology laboratory is buying it? Is the product dead in the water? If it both saves money and is more reliable than humans, what is the issue?
Is someone with industry inside knowledge able to explain it for me please?
Ann: LBT RECEIVES $848,673 R&D TAX INCENTIVE, page-4
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
-0.002(11.8%) |
Mkt cap ! $23.31M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.6¢ | 1.4¢ | $66.59K | 4.467M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 486857 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 702681 | 1 |
View Market Depth
| Last trade - 15.53pm 28/06/2024 (20 minute delay) ? |
| LBT (ASX) Chart |